Table 2. Effects of doxorubicin and deracoxib combination treatment for 72 hr on cell cycle kinetics of CMT-U27 cells.
| Drugs | Concentration | G0/G1 (%) | S (%) | G2/M (%) |
|---|---|---|---|---|
| Control | - | 54.51 ± 2.68 | 29.05 ± 1.68 | 16.44 ± 1.24 |
| DOX | 0.9 µM | 56.6 ± 4.24 | 34.83 ± 2.53 | 8.51 ± 1.14 |
| DOX + DER | 0.9 µM + 50 µM | 84.49 ± 3.60 | 15.30 ± 2.08 | 0.21 ± 0.04a) |
| DOX + DER | 0.9 µM + 100 µM | 84.96 ± 1.45 | 14.83 ± 2.65 | 0.21 ± 0.03a) |
| DOX + DER | 0.9 µM + 250 µM | 91.34 ± 3.64 | 7.16 ± 1.32a) | 1.49 ± 0.18a) |
| DOX | 0.09 µM | 86.93 ± 4.99 | 12.92 ± 1.72 | 0.14 ± 0.04 |
| DOX + DER | 0.09 µM + 50 µM | 89.58 ± 5.46 | 10.30 ± 1.06 | 0.12 ± 0.03 |
| DOX + DER | 0.09 µM + 100 µM | 89.13 ± 4.49 | 10.84 ± 1.50 | 0.20 ± 0.04 |
| DOX + DER | 0.09 µM + 250 µM | 89.79 ± 2.85 | 10.1 ± 1.46 | 0.10 ± 0.02 |
Each value represents the mean ± SE of three experiments. a) P<0.05 compared with the 0.9 µM doxorubicin-treated group. DOX, doxorubicin; DER, deracoxib.